BioNTech SE (0A3M)
LSE
Closed
Aug 24, 2026
Day's Range
110.6052 wk Range
79.51Overview - 0A3M - BioNTech SE
Key Statistics
Valuation
Enterprise Value
7.57B
P/E (Trailing)
‪6.52‬
P/E (Forward)
‪6.50‬
PEG Ratio
‪0.06‬
Price / Sales (TTM)
‪3.51‬
Price / Book
‪1.41‬
EV / EBITDA
‪1.09‬
Profitability
Gross Margin
‪8.14%‬
Profit Margin
‪47.64%‬
Operating Margin
‪63.94%‬
Return on Assets
‪16.92%‬
Return on Equity
‪23.82%‬
Ownership
Shares Outstanding
251.20M
Float
86.11M
Held by Insiders
‪65.11%‬
Held by Institutions
‪17.59%‬
Price stats
Beta
‪0.24‬
50-Day Avg
‪92.84‬
200-Day Avg
‪97.09‬
Dividends
Payout Ratio
‪0.00%‬
Frequency
Monthly
Market Cap - 0A3M - BioNTech SE
Peers - 0A3M - BioNTech SE
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0A3MLSEBioNTech SE30.39BMarket Cap-0.89%52-week change6.20P/E (Trailing)‪47.64%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.34BMarket Cap+29.12%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+31.55%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.10BMarket Cap+82.56%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.47%52-week change128.71P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0A3M - BioNTech SE
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, it leverages advanced platforms like mRNA technology, next-generation…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
